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Aim: To compare the diagnostic values and limitations of quantitative fluorescent polymerase chain reaction (QF-PCR) 
and conventional cytogenetic analysis in prenatal diagnosis of chromosomal abnormalities. 
Methods: A prospective study included simultaneous QF-PCR and cytogenetic analysis of 133 prenatal samples 
routinely obtained by amniocentesis or chorionic villus sampling (CVS). Additionally, QF-PCR analysis was performed 
on 14 tissue samples collected after termination of pregnancy (TOP) for which karyotyping could not be performed due 
to culture failure.  
Results: Among 133 analyzed prenatal samples, chromosomal abnormalities were diagnosed in 12 cases (9%), 
including 10 cases of numerical chromosomal aberrations and two cases with unbalanced structural rearrangements. 
Nine out of 12 chromosomal abnormalities were also detected with QF-PCR. However, all cases of major aneuploidies 
were successfully disclosed with QF-PCR, resulting in 100% detection rate for chromosomes 21, 18, 13, X and Y. 
Using a set of markers specific for chromosomes 21, 18 and 13, QF-PCR analysis of tissues collected after TOP 
revealed chromosomopathy in 21.4% of cases (two cases of trisomy 18 and one triploidy). A comparison of STR 
markers confirmed monozygosity in two monochorionic/diamniotic twin pregnancies. 
Conclusion: QF-PCR has been shown as a rapid and reliable method for prenatal diagnosis of the most common 
chromosomal aneuploidies, and as an adequate alternative to conventional karyotyping in cases where cytogenetic 
analysis is not possible due to failure of culturing process. However, conventional cytogenetics still presents a gold 
standard for the detection of structural aberrations and rare aneuploidies. 
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INTRODUCTION 
Chromosomal abnormalities have been ascertained as 
the most common cause of intellectual disability
1
 and 
are associated with approximately 15% of major 
congenital anomalies in the human population.
2
 
According to EUROCAT data, a total prevalence of 
unbalanced chromosomal aberrations of 43.8 per 10000 
births was recorded in Europe for the period 2000-
2006, while trisomies 21, 18 and 13 together with 
triploidy and sex chromosome aneuploidies accounted 
for 86% of all registered chromosomophaties.
3
  
Over the last few decades, prenatal diagnosis of 
chromosomal abnormalities has been routinely 
performed as part of obstetric management of high-risk 
pregnancies, assessed by noninvasive screening 
methods. Conventional cytogenetic analysis of cultured 
fetal cells obtained by one of the invasive procedures, 
i.e. amniocentesis or chorionic villus sampling (CVS), 
is still considered the gold standard as a method that 
enables the detection of numerical aberrations, as well 
as unbalanced and balanced rearrangements of all 
chromosomes. However, the method is labor-intensive, 
expensive and, most importantly, time-consuming, 
with an average reporting time of 10 to 14 days. 
Parental anxiety due to the extended wait for results 
and the necessity of rapid diagnosis in advanced 
pregnancies and those with a particularly high risk of 
chromosomal abnormalities have prompted the 
implementation of techniques that enable faster 
diagnosis assessment. Quantitative fluorescent 
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polymerase chain reaction (QF-PCR) was firstly 
introduced in the early 1990s
4
, and it has been proven 
as an economic, simple and reliable method with the 
high specificity and sensitivity for detection of the most 
common aneuploidies. The technique is based on the 
amplification of highly polymorphic DNA sequences 
(short tandem repeats, STR) located on target 
chromosomes, followed by relative quantification of 
amplified markers. As a result of the avoidance of 




A number of recent studies and guidelines have been 
directed towards the ascertainment of the most 
appropriate approach regarding the effectiveness and 
cost efficiency of methods used for prenatal diagnosis 
of chromosomal abnormalities. Since its 
implementation, QF-PCR has been performed in 
combination with conventional karyotyping as a rapid 
test for the detection of major aneuploidies. Soon after, 
the question of whether it could be used as a stand-
alone method was raised. Therefore, two different 
strategies have been proposed. In one, the choice 
between QF-PCR and full karyotype analysis is given 
to women with no increased risk of a structural 
chromosomal abnormality, while, according to more 
commonly reported guidelines, rapid testing is 
performed on all prenatal samples, followed by 
conventional cytogenetics in those with observed fetal 
ultrasound anomalies or a familial history of 
chromosomal rearrangements.
8, 9
     
The aim of this study was to compare the diagnostic 
values and limitations of both QF-PCR and 
conventional cytogenetic analysis in prenatal diagnosis 
of chromosomal abnormalities. 
 
 
MATERIAL AND METHODS 
A prospective study encompasses the analysis of 133 
prenatal samples from 128 women (five twin 
pregnancies), routinely referred for prenatal diagnosis 
due to advanced maternal age (≥35 years), the presence 
of the abnormal ultrasound finding, a positive maternal 
serum screening test, or other factors associated with 
an increased risk of chromosomal abnormalities 
(personal/family history of chromosomal abnormality, 
recurrent miscarriages). Only those cases analyzed by 
both QF-PCR and conventional karyotyping were 
included in the study. Abnormal ultrasound findings 
detected at the first-/ second-trimester examination 
included various major abnormalities and minor/soft 
markers associated with aneuploidies. All patients 
received genetic counseling, including information 
about advantages and limitations of the invasive 
procedure and methods used for chromosomal analysis; 
routine written consent was obtained prior to the 
invasive procedure. Ethical approval was acquired 
from institutional Ethics committee of Clinical Hospital 
“Sveti Duh”, Zagreb. 
Between 15 and 20 ml of amniotic fluid was obtained 
by amniocentesis; 2-3 ml was designated for the QF-
PCR analysis and the rest was used for a routine cell 
culturing. CVS was performed transabdominally, and 
at least 15-20 mg of chorionic villi was acquired. A 
short-term cytotrophoblast and mesenchymal stroma 
cultures were set up, and the remainder of the sample 
was used for DNA isolation.  
The study also included 14 tissue samples obtained 
after termination of pregnancy (TOP) for which routine 
cytogenetic analysis could not be performed due to 
culture failure, and solely the QF-PCR analysis was 
carried out on the DNA isolated from fetal skin 
samples. The indications for chromosomal analysis 
were presence of the fetal malformations, recurrent 
miscarriage (three or more consecutive miscarriages) or 




Chelex 100 method (Bio-Rad Laboratories Inc, 
Hercules, CA) was used to extract DNA from all 
samples, following the protocol described in the user’s 
manual.
10
 In very few cases when slightly bloodstained 
pellet was observed after amniotic-fluid centrifugation, 
two-step red cell lysis and water wash was performed 
followed by centrifugation for 5 minutes at 13.000 rpm. 
In these cases, as additional precautionary step, 
maternal buccal swab sample was tested in parallel 
with the amniotic fluid samples. 
For the first 115 samples, QF-PCR analysis was 
performed as described in the previously published 
article.
11
 Details of primers used in the QF-PCR 
multiplex are shown in Table 1.  
Lyophilized primers (10 nM) were ordered from 
buffer (10 mM Tris·Cl, 1 mM EDTA, pH 8.0) to each 
forward and reverse primer. Primer mix for the full 
assay was prepared in the total volume of 50 µl, and for 
each of the back-up assays the total volume of primer 
mix was 25 µl. Primer concentrations are given in 
Table 1. Primer mix was tested, aliquoted and stored at 
20˚C. To prepare the PCR reaction mix, 2x QIAGEN 
Multiplex PCR Master Mix (Hilden, Germany) was 
used. The PCR reaction mix was prepared in the total 
volume of 15 µl, respecting the primer mix ratio as 
noted in QIAGEN Multiplex PCR Handbook 
10/2010
12
. As recommended in the previously 
published article
11
, but proportionally adjusted to the 
reduced volume of PCR reaction, 6 µl of DNA 
template was added to the PCR reaction mix. 
Microsatellite loci on chromosomes 13, 18 and 21 were 
amplified in a single-tube assay with the following 
PCR reaction conditions: initial denaturation was set up 
at 95°C for 15 minutes, followed by 25 cycles of 
denaturation at 94°C for 30 seconds, annealing step at 
57°C for 1 minute 30 seconds, and elongation at 72°C 
for 1 minute 30 seconds. The final elongation step was 
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Primer sequence 5' - 3' 
Concentration / 
primer mix (M) 
Final concentration / 













D13S305 13q13.3 430-465 
(F) HEX-GCCTGTTTGAGGACCTGTCGTTA  
(R) TGGTTATAGAGCAGTTAAGGCAC 
3 2 0.30* 0.20 
D13S628 13q31.1 425-470 
(F) NED-TAACATTCATTGTCCCTTACAGAT 
(R) GCAAGGCTATCTAACGATAATTCA 
8 2 0.80* 0.20 
D13S634 13q21.33 385-440 
(F) 6-FAM-GGCAGATTCAATAGGATAAATAGA 
(R) GTAACCCCTCAGGTTCTCAAGTC 
1.5 2 0.15* 0.20 
D13S742 13q12.12 235-315 
(F) HEX-ATAACTGGGCTAGGAATGGAAATA 
(R) GACTTCCCAATTCAGGAGGACT 
2 NA 0.20 NA 
D18S978 18q12.3 180-220 
(F) NED-GTAGATCTTGGGACTTGTCAGA 
(R) GTCTCCCATGGTCACAATGCT 
4 2 0.40* 0.20 
D18S386 18q22.1 330-400 
(F) HEX-TGAGTCAGGAGAATCACTTGGAAC 
(R) CTCTTCCATGAAGTAGCTAAGCAG 
2 2 0.20 0.20 
D18S499 18q22.1 390-410 
(F) NED-AGATTACCCAGAAATGAGATCAG 
(R) GAAAATGTAGAAGTGAGTCACCT 
6 2 0.60* 0.20 
D18S391 18p11.31 140-180 
(F) HEX-GGACTTACCACAGGCAATGTGACT 
(R) CTGGCTAATTGAGTTAGATTACAA 
1 2 0.10* 0.20 
D18S535 18q12.3 455-500 
(F) 6-FAM-CAGCAAACTTCATGTGACAAAAGC 
(R) CAATGGTAACCTACTATTTACGTC 
1.5 2 0.15* 0.20 
D21S11 21q21.1 225-280 
(F) 6-FAM-TTTCTCAGTCTCCATAAATATGTG 
(R) GATGTTGTATTAGTCAATGTTCTC 
2 2 0.20 0.20 
D21S1270 21q22.11 285-340 
(F) 6-FAM-CTATCCCACTGTATTATTCAGGGC 
(R) TGAGTCTCCAGGTTGCAGGTGACA 
2 2 0.20 0.20 
D21S1411 21q22.3 256-340 
(F) ATAGGTAGATACATAAATATGATGA 
(R) NED-TATTAATGTGTGTCCTTCCAGGC 
4 2 0.40* 0.20 
D21S1435 21q21.3 160-200 
(F) 6-FAM-CCCTCTCAATTGTTTGTCTACC 
(R) ACAAAAGGAAAGCAAGAGATTTCA 
8 2 0.80* 0.20 
D13S252 13q12.1 270-320 
(F) 6-FAM-GCAGATGTACTGTTTTCCTACCAA 
(R) AGATGGTATATTGTGGGACCTTGT 
NA 2 NA 0.20 
D13S762 13q31-q32 270-320 
(F) HEX-AATGAGATTGCTGGGTCAGA 
(R) HEX-AAT GAG ATT GCT GGG TCA GA 
NA 2 NA 0.20 
D18S1002 18q11-q11 340-370 
(F) 6-FAM-GTT TGA TGG GAG GAA GCT ATC TAT 
(R) GTG AAG TAG CGG AAG GCT GTA AT 
NA 2 NA 0.20 
IFNAR 21q22.1 370-410 
(F) NED-CATTTGATCTTAGCCATCTATTGC 
(R) ACTATGCAGCCATTTGAAAGACTA 
NA 2 NA 0.20 
D21S226 21q22.1 440-470 
(F) 6-FAM-GCAAATTTGTGGATGGGATTAACAG 
(R) AAGCTAAATGTCTGTAGTTATTCT 
NA 2 NA 0.20 
Legend: The markers are amplified in three chromosome-specific assays. Marker and primer information are given in Mann K, Donaghue C, Fox SP, 
Docherty Z, Ogilvie CM. Strategies for the rapid prenatal diagnosis of chromosome aneuploidy. European Journal of Human Genetics. 2004;12:907-
915. Primer mix for full assay was prepared in total volume of 50 l while the primer mix of each back-up assay was 25 l. Total volume of PCR 
reaction was 15 l. 
*For each back-up assay, final concentration of each primer in 15 l PCR reaction volume was 0.2 M. 
NA - not applicable 
 
 
set up at 72°C for 20 minutes. A total of 13 STR loci 
were amplified simultaneously when the Full Assay 
was used. Markers used for the detection of 
chromosome 21 are located in the Down syndrome 
critical region (21q22.1–21q22.3), except of D21S11 
which is located near the centromere. Four markers on 
chromosome 13 and five on chromosome 18 are 
distributed along each chromosome in order to increase 
the likelihood of detecting unbalanced chromosome 
rearrangements. In cases where two or more of the Full 
Assay markers on any one of these chromosomes were 
found to be uninformative (homozygous), the back-up 
sets were used. The chromosome-specific back-up sets 
were also used to confirm any abnormal results, as well 
as in cases when maternal sample was tested in 
parallel. This was done in order to compare STR 
profiles and confirm or exclude the fetal origin of the 
predominant cell population if a slightly bloodstained 
pellet was observed in amniotic fluid sample. In each 
chromosome-specific set, almost all markers amplified 
in Full Assay were repeated in order to confirm sample 
identity. There were no cases when additional markers 
were mostly homozygous. Since there were no cases in 
which, of total markers tested for each chromosome, 
more than two markers were uninformative, all 
detected chromosomal abnormalities were confirmed. 
Otherwise, such results would be considered 
inconclusive. All markers are shown in Table 2. 
For 32 samples, DNA fragments were amplified using 
the Aneufast™ QF-PCR Kit (Genomed AG, Wollerau 
Switzerland), as described in the user’s manual.12 
These samples were received at the point when the in-
house kit was no longer in use because we had already 
switched to the abovementioned commercially 
available kit. Two sets of markers multiplexes S1 and 
S2 enabled the simultaneous amplification of five STR 
loci on each of the autosomes 13, 18 and 21; in 
addition   to  three  pseudoautosomal  (DXYS267,  X22  
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Table 2. In-house set of markers used for rapid diagnosis of 
trisomies 13, 18 and 21 used for analysis of 115 samples. 
Full Assay 
marker set 
Chromosome-specific back-up marker sets 
Assay 13 Assay 18 Assay 21 
D13S305 D13S305 D18S978 D21S11 
D13S628 D13S628 D18S386 D21S1270 
D13S634 D13S634 D18S499 D21S1411 
D13S742 D13S252* D18S391 D21S1435 
D18S978 D13S762* D18S535 IFNAR* 
D18S386  D18S1002* D21S226* 
D18S499    
D18S391    
D18S535    
D21S11    
D21S1270    
D21S1411    
D21S1435    
Legend: * - extra markers not included in Full Assay 
 
 
and DXYS218) and one X-linked STRs, as well as two 
non-polymorphic sequences, Amelogenin (AMXY) 
and SRY (amplified for sex determination). The 
chromosome-specific back-up sets were also used in 
cases as described earlier. All markers are shown in 
Table 3. 
Amplified fragments were separated by capillary 
electrophoresis on genetic analyzer 3130 (Applied 
Biosystems, Foster City, CA, USA). Fragment size was 
determined by internal size standard by 
GeneMapper
®
ID-X software (Applied Biosystems, 
Foster City, CA, USA). Results were interpreted in 
accordance to the user’s manual.13 STR marker 




Cytogenetic analysis and FISH 
Cytogenetic analysis of prenatal samples was 
performed on cultured amniocytes or short-term 
cytotrophoblast/mesenchymal stroma cultures 
following European Cytogeneticists Association 
guidelines.
14
 Clinically significant chromosomal 
abnormalities were considered to be those associated 
with high or uncertain risk of adverse clinical outcome, 
including aneuploidies of all chromosomes, unbalanced 
structural aberrations and marker chromosomes.
15
 
Inherited balanced translocations and inversions were 
considered as chromosomal aberrations with no or low 
risk of adverse outcome. For parental karyotyping, a 
short-term phytohemagglutinin-stimulated whole blood 
culturing was used. Fluorescence in situ hybridization 
(FISH) was carried out with commercially available 
DiGeorge region probes (N25, TUPLE, TBX1), 
satellite enumeration probe D14Z1/D22Z1, SHANK3 
(Kreatech FISH probes, Leica Biosystems, Nussloch, 
Germany), and BCR locus specific probe (Vysis, 





Comparisons for categorical variables were made using 
Fischer’s exact test, and for continuous variables 
between two groups using the Mann-Whitney U-test.  
P≤0.01 was considered statistically significant.  
Statistical analysis was carried out using R 
programming language (version 3.2.0). 
 
 
Table 3. Markers amplified with the Aneufast™ QF-PCR Kit used for analysis of additional 32 samples. 
S1 S2 MXY M21 M18 M13 
AMXY  SRY SRY D21S1411 D18S386 D13S631 
DXYS267  X22 AMXY D21S1435 D18S391 D13S634 
D21S1414  DXYS218 HPRT  D21S1437*  D18S858*  D13S742* 
D21S1446 HPRT TAF9L* D21S1412*  D18S499* D13S628* 
D21S1442  D21S1411 DXYS156*  D21S1809* D18S1002*  
D18S535 D21S1435 SBMA*    
D18S391  D13S634  DXS6803*     
D18S976  D13S258 DXS6809*    
D13S797 D18S386 DXS8377*    
D13S631 D18S390     
D13S305      
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RESULTS 
Indications for referrals and maternal age 
distribution 
A total of 147 samples were analyzed, while 
simultaneous QF-PCR and cytogenetic analysis were 
performed for 131 amniotic fluid and two chorionic 
villus samples, and QF-PCR only was performed for all 
14 tissue samples collected after TOP. The indications 
for invasive prenatal diagnostic procedures of all 128 
pregnant women (including five twin pregnancies) are 
given in Table 4. QF-PCR analysis of fetal tissue 
samples collected after TOP was performed due to the 
presence of the fetal malformations in 57.2% of cases, 
recurrent miscarriages in 21.4% or because of fetal loss 
in the second trimester of pregnancy in 21.4% of cases. 
Among all cases, an abnormal first-/second-trimester 
ultrasound scan was observed in 52 fetuses (33.1%). 
The mean maternal age was 34.9 years (range 18 - 47 
years), without a statistically significant difference 
between the group of women who underwent invasive 
procedure and those who suffered spontaneous loss of 
pregnancy (mean maternal age of 35.1 years vs. 33 
years) (P=0.1, Mann-Whitney U-test).  Furthermore, 
mean maternal age of 35.5 years (range 26 - 46 years) 
was observed within the group with diagnosed 
chromosomal abnormality, similarly to those receiving 
normal reports (mean 34.8 years, range 18 - 47). The 
mean gestational age at the time of diagnosis was 17.3 
and 17 weeks for samples obtained by invasive 
procedure and those collected after TOP, respectively. 
 
 
Karyotyping and QF-PCR results 
A total of 12 clinically significant chromosomal 
aberrations were revealed by cytogenetic analysis of 
133 prenatal samples, including 10 cases of numerical 
chromosomal abnormalities and two cases with 
unbalanced structural rearrangement (Table 5). Using 
an in-house designed set of STR markers for 
chromosomes 21, 13 and 18 for QF-PCR analysis of 
the first 101 cases, and the Aneufast commercial kit for 
the following 32 samples, four cases of trisomy 21 and 
one triploidy (Figure 1) were detected. Since an in-
house method was used, four cases of sex chromosome 
aneuploidies remained undisclosed; however, all four 
cases were subsequently evaluated and confirmed with 
the Aneufast kit. Therefore, a QF-PCR detection rate of 
100% was recorded for the most common aneuploidies. 
There was no difference in the detection rate between 
the two sets of markers used, other than the detection 
of sex chromosome abnormalities. In case of 
45,X/46,XX mosaicism, a QF-PCR analysis also 
indicated abnormal karyotype, since the percentage of 
45,X cell line was 90%. Overall, nine out of 12 
chromosomal abnormalities (75%) were detected with 
QF-PCR. 
Table 4. Indications for invasive diagnostic procedure in a group 










Maternal age alone 36 (31.0) 1 (8.3) 37 (28.9) 
Ultrasound anomaly* 29 (25.0) 8 (66.7) 37 (28.9) 
Maternal serum 




4 (3.4) 2 (16.7) 6 (4.7) 
Other 20 (17.3) 0 20 (15.6) 
Total 116 (100) 12 (100) 128 (100) 
Legend: N – number of cases 
 
 
Two cases of unbalanced structural rearrangements and 
one autosomal trisomy, i.e. clinically significant 
chromosomal aberrations, have remained undisclosed 
by QF-PCR analysis (Table 5). In the first case a 41-
year-old woman, G2P1, underwent amniocentesis at 16 
weeks of pregnancy due to advanced maternal age 
alone. Fetal ultrasound was unremarkable, and she had 
one healthy child. A mosaicism for supernumerary 
marker chromosome (SMC) was diagnosed by 
conventional   karyotyping.   FISH  analysis  showed  a  
 
  
Table 5. Chromosomal abnormalities detected by cytogenetic and 
QF-PCR analysis of 133 prenatal samples (amniotic fluid and 





CHA detected among 
prenatal samples 
12 9 
Trisomy 21 4 4 
Triploidy 1 1 
45,X 2 2 
45,X (90%)/46,XX (10%) 1 1 





46,XY,der(4),t(1;4)(q23;p15.2)mat 1 - 
47,XX,+9 1 - 
CHA detected among tissue 
samples collected after TOP* 
- 3 
Trisomy 18 - 2 
Triploidy - 1 
Legend: CHA - chromosomal abnormalities; TOP - termination of 
pregnancy; * - Cytogenetic analysis could not be performed due to 
culture growth failure 
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Figure 1. QF-PCR detection of triploidy using Full assay with 
chromosome 21, 18 and 13 specific markers. All 13 markers used 




chromosome 22 origin of SMC, comprising only the 
short arm and pericentromeric region, whilst it was 
negative for the DiGeorge region (3 probes), the BCR 
region and the control probe region 22q13 (Figure 2). 
A mos 47,XX,+mar.ish der(22)(D22Z1+,N25-,TUPLE, 
TBX1-,BCR-,SHANK3-)/46,XX karyotype was 
disclosed, with the percentage of cell line with SMC of 
90%. Parental karyotyping revealed the maternal origin 
of SMC, and a healthy newborn was delivered at term. 
In the second case, a 19-year-old woman, G2P1, was 
referred to our Clinic at 14 weeks of pregnancy due to 
an ultrasound finding of fetal cystic hygroma and a 
combined test showing risk for T21 of 1:20, and 
T13/T18 of 1:5. A derivative chromosome 4 was 
detected by cytogenetic analysis of cultured chorionic 
villi. In order to ascertain the origin of the derivative 
chromosome, parental karyotypes were performed, 
disclosing a balanced reciprocal translocation 
1q23;4p15.2 in the mother. Thus, the fetal karyotype 
was designated as 46,XY,der(4),t(1;4)(q23;p15.2)mat. 
After genetic counseling, the parents opted for the 
termination of pregnancy. The third case, a 41-old-
women G2P1, was referred because of a high risk for 
T13/T18 (1:15) obtained by combined screening. CVS 
was performed at 13+4 weeks of gestation, and non-
mosaic trisomy 9 (47,XX,+9) was disclosed. The 
pregnancy, however, ended in a spontaneous abortion. 
In addition, cytogenetic analysis detected one case of 
balanced Robertsonian translocation of maternal origin 
(45,XX,dic(13;14)(p11.2;q11.2)mat).  
Furthermore, QF-PCR analysis of tissues collected 
after TOP revealed two cases of trisomy 18 and one 
triploidy, which would otherwise not be detected since 
the karyotyping could not be performed due to culture 
growth failure. In summary, a total of 15 chromosomal 
abnormalities were revealed during the study, 12 
detected by conventional karyotyping, and three 
additionally with QF-PCR. Aneuploidies involving 
chromosomes 21, 18, 13, X and Y accounted for 80% 
of all determined aberrations. Out of 133 samples 
obtained by invasive procedures chromosomopathies 
were detected in 9% of cases, in comparison with the 
detection rate of 21.4% revealed within samples 
collected after TOP (P=0.01). Furthermore, a 
significantly higher proportion of trisomy 18 cases 
were detected within samples collected after TOP 
(14.3% vs. 0% within invasive procedures, P=0.01). 
Amniocentesis was performed in five twin pregnancies; 
in four cases the indication for prenatal diagnosis was 
ultrasound abnormality present in a single or in both 
twins, and one patient was referred because of a 
previous pregnancy with chromosomal abnormality. 
Normal karyotypes were obtained in all cases, while 
the comparison of STR markers confirmed 




As a rapid, cost-effective and reliable test for the 
detection of the most common aneuploidies, QF-PCR 
has been widely established as a part of routine 
prenatal diagnosis of chromosomal abnormalities, 
mainly performed together with conventional 
karyotyping. By combining QF-PCR and cytogenetic 
analysis, a total of 15 chromosomopathies were 
revealed in the present study, while aneuploidies of 
chromosomes 21, 18, 13, X and Y, together with 
triploidy accounted for 80% of detected aberrations, 
which is in concordance with the proportion of major 
aneuploidies observed in the general population.
3
  
To date, a number of studies and reviews referred 
toward he determination of accuracy of QF-PCR have 
reported the detection rates for the non-mosaic major 
aneuploidies in a range of 98.6% to 100%, and the 
specificity of 100%.
6, 16, 17
 Comparably, all cases 
involving aneuploidies of chromosomes 21, 18, 13, X 
and Y were detected in our study, without false positive 
results. In contrast, the reported proportion of detected 
mosaicisms was approximately 60%, including only 
those with the percentage of abnormal cell line above 
20-30%. The present study included only one case of 
mosaicism, which was also indicated by QF-PCR, 
since cell lines with monosomy X accounted for 90%. 
Although the inability of detection of low-level 
mosaicisms is stated as one of the main disadvantages 
of  QF-PCR,  a survey  of  Donaghue et al.
18 
 showed  a  
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Figure 2. A) Karyogram of the fetus with supernumerary marker chromosome derived from chromosome 22. B) FISH analysis of SMC using 




discrepancy in mosaicism detection between QF-PCR 
and cytogenetic analysis of uncultured and cultured 
CVS and amniotic fluid samples. Out of 18 mosaic 
cases, 12 were revealed by QF-PCR and eight by 
cytogenetics. Although the finding of mosaicism in 
CVS could be confined only to placenta, mosaicisms 
detected in uncultured amniotic fluid samples are very 
likely to represent a real fetal genotype. If we take into 
account that the culturing process could result in the 
overgrowth of a single cell line, QF-PCR analysis of 
uncultured samples may reflect more similar 
proportions with those present in vivo. Thus, a 
combined approach using both QF-PCR and 
cytogenetic analysis presents the best strategy for the 
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detection of mosaicism and the interpretation of the 
obtained results. 
Of the 12 chromosomopathies observed among 
prenatal samples, three (25%) were undisclosed by QF-
PCR. Undetected aberrations included trisomy 9, 
karyotype with supernumerary marker chromosome 
resulting in the normal phenotype, and derivative 
chromosome 4. In cases with poor prognosis, i.e. 
trisomy 9 and derivative chromosome 4, the indications 
for prenatal diagnosis were a positive combined 
screening test and abnormal ultrasound finding, 
respectively, highlighting the necessity of conventional 
karyotyping especially in pregnancies associated with a 
high risk of chromosomal abnormalities. In both cases 
with the structural aberrations, abnormalities were 
inherited from parents. These cases emphasize the 
value of classical cytogenetic analysis, not only for the 
disclosure of pathological karyotypes in the current 
pregnancy, but also providing genetic information to 
evaluate the risk of having offspring with chromosome 
aberrations in subsequent pregnancies.    
Using an in-house set of markers specific for 
chromosomes 21, 18 and 13, sex chromosome 
aneuploidies could not be detected, and therefore three 
cases with the Turner syndrome (two non-mosaics and 
45,X/46,XX mosaicism), and one case of 47,XXX 
remained undisclosed (Table 5).  However, subsequent 
evaluation with Aneufast kit indicated the existence of 
sex chromosome aneuploidies in all four cases. In some 
genetic laboratories, QF-PCR sex chromosome testing 
is performed only in pregnancies with evidenced 
ultrasound anomalies suggestive for the Turner 
syndrome. As stated, the diagnosis of aneuploidies 
such as 47,XXY, 47,XXX or 47,XYY is of debatable 
value anyway, since these are associated mainly with a 
normal or mild clinical phenotype.
8, 19
 However, a 
routine application of sex chromosome aneuploidy 
testing enables an accurate and rapid assessment of 
diagnosis, providing useful information for further 
pregnancy management and allowing parents more 
time to make a decision. 
Several studies regarding the comparison of QF-PCR 
and conventional cytogenetics in the detection of 
clinically significant chromosomopathies, and potential 
usage of QF-PCR as a stand-alone method have been 
reported. Although according to the majority of those 
reports >90% of the clinically significant chromosomal 
abnormalities have been detected by QF-PCR
6, 16, 17, 19-
22
, some authors have reported that approximately 30% 
of such abnormalities stayed undisclosed with QF-PCR 
analysis.
23, 24
 The variability in reported results is 
primarily obtained due to differences in the indications 
for prenatal testing and determination of clinical 
relevance of diagnosed chromosomopathies. A 
proportion of 25% of clinically significant aberrations 
undetected by QF-PCR in our study could be explained 
by the high percentage of women undergoing the 
invasive procedure due to abnormal ultrasound findings 
(28.9%) or positive maternal serum screening test 
(26.6%) (Table 4). Considering the indication for 
referrals, it has been reported that less than 7% of 
clinically significant abnormalities undetected by QF-
PCR are observed within the group of women referred 
because of advanced maternal age alone
17, 21, 25
, which 
was expected since those women have lover risk of 
chromosomopathies in comparison with cases when 
ultrasound anomaly or positive biochemical screening 
is found. In contrast, when ultrasound abnormality or 
positive biochemical screening are present, false 
negative results obtained by QF-PCR increase to an 
approximately 30%.
17, 25, 26
 The presence of ultrasound 
anomaly or higher risk obtained by biochemical 
screening are indicative for higher risk of 
chromosomopathy, and not only for the most common 
aneuploidies but also other chromosomal aberrations. 
For example, an ultrasound finding of cystic hygroma 
carries a risk of chromosomal abnormalities of 
approximately 50%, in comparison with the maternal 
age of 35 years in which the risk of Down syndrome is 
1 in 246.
27, 28
Thus, our study likewise emphasizes the 
necessity of karyotype analysis in cases with abnormal 
ultrasound findings and maternal serum screening tests.  
Although the possibility of replacement of the 
conventional karyotyping with QF-PCR for certain 
referrals has been investigated by a number of studies, 
conciliated conclusions have not yet been designated. 
To date, QF-PCR has been proven as a reliable, fast 
and cost-effective method for the detection of the most 
common aneuploidies; nevertheless, a proportion of 
clinically significant chromosomopathies could not 
been disclosed, as well as balanced rearrangements and 
some aberrations with no adverse outcome for the 
current pregnancy, raising a number of ethical 
questions. However, in some countries strategies based 
on rapid testing performed for all prenatal samples, 
followed by conventional cytogenetics in those cases 
with observed fetal ultrasound anomalies or a familial 
history of chromosomal rearrangements are 
implemented in the routine praxis.
6, 8, 9
 Using this 
approach, Hills et al.8 reported a proportion of 0,3% of 
chromosomal abnormalities misdiagnosed by QF-PCR, 
while cases with poor clinical outcome accounted for 
0,069%. In contrast, in Croatia rapid QF-PCR testing is 
still not routinely performed as a part of prenatal 
diagnostics, and the guidelines toward its 
implementation have not yet been established. 
Therefore, this study could implicate the assessment of 
its utility as a standard procedure. Furthermore, 
misdiagnosed cases observed in the present study 
highlight the importance of full karyotyping in cases 
with a substantial risk of chromosomal abnormalities, 
but also the necessity of counseling parents about the 
advantages and limitations of chosen diagnostic 
procedures.    
About 10-15% of all recognized pregnancies end in a 
spontaneous abortion
29
, while chromosomal 
abnormalities are considered as the most common 
cause, found in approximately 60% of first-trimester 
miscarriages.
30
 Chromosomal analysis of products of 
conception is routinely performed by conventional 
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karyotyping of cultured chorionic villi or fetal skin 
samples. However, difficulties such as culture failure 
due to microbial contamination or samples obtained 
from nonviable fetuses, poor quality samples, or 
maternal cell contamination, lead to the inability of 
diagnosis ascertainment in up to 30% of investigations. 
As a method which does not require the culturing 
process, QF-PCR has been shown as an adequate 
alternative to conventional karyotyping, with a success 
rate of over 95%.
31
 Maternal cell contamination can 
also be an issue for the QF-PCR method. In our 
experience, two-step red cell lysis and water wash 
followed by centrifugation is worthwhile since no extra 
STR alleles in the QF-PCR profiles that might be 
doubtful for the interpretation of results were observed. 
For amniotic fluids, it is possible to analyze samples 
containing about 20% of visible blood in the cell 
pellets without noticing extra STR alleles in the QF-
PCR profiles. If special precautions are undertaken to 
identify the source of the blood contamination, either 
maternal or fetal, it is possible to undertake lysis/wash 
step for heavily bloodstained amniotic fluids as well.
13
 
It is not likely that this can completely resolve potential 
doubts, but it might be possible to draw certain 
conclusions based on the maternal / fetal allele ratio 
and comparison of their STR profiles if the maternal 
sample is tested as well. However, the results should 
not be reported officially, and severely bloodstained 
amniotic fluids should be considered as unsuitable for 
QF-PCR diagnosis. 
According to recent reports, by using QF-PCR analysis 
with a set of markers for chromosomes 21, 13 and 18, 
chromosomal abnormalities are detected in a range of 
13% to 17% of analyzed samples.
31, 32
 A slightly higher 
proportion was observed in our study, where QF-PCR 
analysis with an in-house set of markers revealed a 
proportion of 21.4% of abnormal karyotypes. Although 
structural chromosomal aberrations could not be 
detected using QF-PCR, valuable information 
regarding the determination of the cause of pregnancy 
loss, recurrence risk in next pregnancies and the 
management of following pregnancies are obtained. 
Twin pregnancies always require special attention 
during obstetric management due to the increased risk 
of preterm delivery, fetal growth restriction and higher 
rate of perinatal mortality and morbidity. Furthermore, 
monozygotic twins are even more frequently associated 
with complications, mainly because of twin-twin-
transfusion-syndrome (TTTS) appearance, while a 
higher rate of intrauterine infections have been 
observed among dizygotic pregnancies.
33
 The 
incidence of twining has been estimated to 
approximately 1 in 65 live births, with the proportion 
of dizygotic twins being settled to 70%, and 
monozygotic to 30%.
34
 Assessment of zygosity is 
routinely based on sonographic identification of 
chorionicity and fetal gender determination, while in 
cases when the invasive procedure was conducted, a 
genetic determination using STR markers could be 
performed. However, the establishment of an accurate 
assertion using the sonographic approach is possible 
only in a case of dichorionic twins of differing sex. In 
the presence of the same gender twins an accuracy of 
67.7% for the determination of monozygotic twins, and 
88.9% for dizygotic twins has been observed.
33
 Thus, 
STR analysis should be considered as a method of 
choice in  cases of dichorionic like-sex twins, in cases 
when chorionicity could not be determined, or when 
discordance in fetal malformations is observed. In the 
present study, all three cases of BC/BA were proved to 
be dizygotic, and both cases of MC/BA were 
determined as monozygotic. The differentiation of 
zygosity is important in planning obstetric management 
of twin pregnancies, as well as counseling parents 
regarding the possible outcome of pregnancy. 
However, it should be considered that monozygosity 
not necessarily denotes the same genetic or 
chromosomal constitution, since discrepancies were 
recorded for a number of chromosomal and genetic 
disorders.
35
 Furthermore, in both monozygotic and 
dizygotic twins, the possibility of blood chimerism 
should be taken into account.
36
  
In conclusion, QF-PCR has been showed as a rapid and 
reliable test for detection of major chromosomal 
aneuploidies, providing rapid results in affected 
pregnancies, and decreasing parental anxiety in cases 
with normal results. However, conventional 
cytogenetics still presents a gold standard for the 
detection of structural aberrations and rare aneuploidies 
in prenatal diagnosis. A combined approach using both 
QF-PCR and cytogenetics is recommended, since it 
provides information important not only for the 
management of the current pregnancy, but also for 
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